Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of BI 1060469 in Healthy Male Volunteers (Single-blind, Placebo-controlled, Randomised, Partly Fixed-sequence, Parallel Group Design) and Effect of Food on the Bioavailability of BI 1060469 (Open-label, Randomised, Two-way Cross-over)
Phase of Trial: Phase I
Latest Information Update: 23 Apr 2014
Price : $35 *
At a glance
- Drugs BI 1060469 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 24 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Dec 2013 According to ClinicalTrials.gov record status changed from recruiting to active, no longer recruiting.
- 11 Nov 2013 New trial record